Literature DB >> 12084735

Visual impairment and blindness in Europe and their prevention.

I Kocur1, S Resnikoff.   

Abstract

The European region currently differs in many aspects, such as political, socioeconomic, and geographical. After substantial political changes at the beginning of the 1990s, the majority of central and eastern European countries started to rebuild their healthcare systems. It is apparent that eastern Europe represents a highly diverse region where the difference among countries broadens year after year. In highly industrialised countries of Europe, the leading causes of childhood serious visual loss are lesions of the central nervous system, congenital anomalies and retinal disorders. In the middle income countries of Europe, congenital cataract, glaucoma and, mainly, retinopathy of prematurity are highly expressed. The major cause of serious visual loss in adults in industrialised countries is age related macular degeneration. The other conditions comprise cataract, glaucoma, diabetic retinopathy, and uncorrected/uncorrectable refractive errors, along with low vision. In people of working age, diabetic retinopathy, retinopathy pigmentosa, and optic atrophy are the most frequently reported causes of serious visual loss. In the middle income countries of Europe, advanced cataract, glaucoma, and diabetic retinopathy are more frequently observed.

Entities:  

Mesh:

Year:  2002        PMID: 12084735      PMCID: PMC1771203          DOI: 10.1136/bjo.86.7.716

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  99 in total

1.  Measuring the burden of childhood blindness.

Authors:  J S Rahi; C E Gilbert; A Foster; D Minassian
Journal:  Br J Ophthalmol       Date:  1999-04       Impact factor: 4.638

2.  The incidence and prevalence of amblyopia detected in childhood.

Authors:  J R Thompson; G Woodruff; F A Hiscox; N Strong; C Minshull
Journal:  Public Health       Date:  1991-11       Impact factor: 2.427

Review 3.  The World Health Organization's programme for the prevention of blindness.

Authors:  B Thylefors
Journal:  Int Ophthalmol       Date:  1990-05       Impact factor: 2.031

4.  Is the incidence of registrable age-related macular degeneration increasing?

Authors:  J Evans; R Wormald
Journal:  Br J Ophthalmol       Date:  1996-01       Impact factor: 4.638

5.  Childhood blindness in Uzbekistan.

Authors:  N K Rogers; C E Gilbert; A Foster; B O Zakhidov; C J McCollum
Journal:  Eye (Lond)       Date:  1999       Impact factor: 3.775

6.  Available data on blindness (update 1994)

Authors:  B Thylefors; A D Négrel; R Pararajasegaram; K Y Dadzie
Journal:  Ophthalmic Epidemiol       Date:  1995-03       Impact factor: 1.648

Review 7.  Preventative ophthalmology. Age-related macular degeneration.

Authors:  N M Bressler; S B Bressler
Journal:  Ophthalmology       Date:  1995-08       Impact factor: 12.079

8.  Visual impairment in Swedish children. III. Diagnoses.

Authors:  J Blohmé; K Tornqvist
Journal:  Acta Ophthalmol Scand       Date:  1997-12

9.  Hereditary disease as a cause of childhood blindness: regional variation. Results of blind school studies undertaken in countries of Latin America, Asia and Africa.

Authors:  C Gilbert; J Rahi; M Eckstein; A Foster
Journal:  Ophthalmic Genet       Date:  1995-03       Impact factor: 1.803

10.  Visual impairment in Danish children 1985.

Authors:  T Rosenberg
Journal:  Acta Ophthalmol (Copenh)       Date:  1987-02
View more
  51 in total

1.  The efficacy of automated "disease/no disease" grading for diabetic retinopathy in a systematic screening programme.

Authors:  S Philip; A D Fleming; K A Goatman; S Fonseca; P McNamee; G S Scotland; G J Prescott; P F Sharp; J A Olson
Journal:  Br J Ophthalmol       Date:  2007-05-15       Impact factor: 4.638

Review 2.  Potential neuroprotective biomolecules in ophthalmology.

Authors:  Mehrdad Afarid; Fatemeh Sanie-Jahromi
Journal:  Int Ophthalmol       Date:  2020-11-12       Impact factor: 2.031

3.  The Prevalence of Visual Impairment in the Adult Population.

Authors:  Christian Wolfram; Alexander K Schuster; Heike M Elflein; Stefan Nickels; Andreas Schulz; Philipp S Wild; Manfred E Beutel; Maria Blettner; Thomas Münzel; Karl J Lackner; Norbert Pfeiffer
Journal:  Dtsch Arztebl Int       Date:  2019-04-26       Impact factor: 5.594

4.  Retinopathy of prematurity: involution, factors predisposing to retinal detachment, and expected utility of preemptive surgical reintervention.

Authors:  David K Coats
Journal:  Trans Am Ophthalmol Soc       Date:  2005

5.  Combined cataract and glaucoma surgery: the effect of pupil enlargement on surgical outcomes (an American Ophthalmological Society thesis).

Authors:  L Jay Katz; Camila Zangalli; Raymond Clifford; Benjamin Leiby
Journal:  Trans Am Ophthalmol Soc       Date:  2013-09

6.  The prevalence of visual impairment and blindness in underserved rural areas: a crucial issue for future.

Authors:  H Hashemi; A Yekta; E Jafarzadehpur; A Doostdar; H Ostadimoghaddam; M Khabazkhoob
Journal:  Eye (Lond)       Date:  2017-04-21       Impact factor: 3.775

7.  [Treatment of recurrent neovascular age-related macular degeneration with ranibizumab according to the PrONTO scheme].

Authors:  A Wolf; L Reznicek; J Muhr; M Ulbig; A Kampik; C Haritoglou
Journal:  Ophthalmologe       Date:  2013-08       Impact factor: 1.059

8.  Phacoviscocanalostomy for open-angle glaucoma with concomitant age-related cataract.

Authors:  Alexandros N Stangos; Anestis Mavropoulos; Gordana Sunaric-Megevand
Journal:  Clin Ophthalmol       Date:  2007-12

Review 9.  Hypoxia-inducible factor-1 (HIF-1): a potential target for intervention in ocular neovascular diseases.

Authors:  Ramya Krishna Vadlapatla; Aswani Dutt Vadlapudi; Ashim K Mitra
Journal:  Curr Drug Targets       Date:  2013-07       Impact factor: 3.465

10.  The prevalence and causes of visual impairment in Tehran: the Tehran Eye Study.

Authors:  A Fotouhi; H Hashemi; K Mohammad; K H Jalali
Journal:  Br J Ophthalmol       Date:  2004-06       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.